10x Genomics (TXG)
(Delayed Data from NSDQ)
$27.59 USD
+0.69 (2.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.92 +0.33 (1.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for 10x Genomics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -255.10 | -166.00 | -58.22 | -542.73 | -31.25 |
Depreciation/Amortization & Depletion | 43.62 | 33.88 | 28.25 | 19.02 | 7.07 |
Net Change from Assets/Liabilities | 18.02 | -39.42 | -87.45 | -50.38 | 44.76 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 178.26 | 137.93 | 96.04 | 356.19 | 14.05 |
Net Cash From Operating Activities | -15.20 | -33.61 | -21.37 | -217.90 | 34.63 |
Property & Equipment | -48.60 | -131.66 | -101.28 | -36.67 | -42.74 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -4.00 | -5.45 | 0.00 | 0.00 |
Investments | 183.02 | -215.23 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -0.92 | 0.00 | 0.00 | -1.73 | -0.03 |
Net Cash from Investing Activities | 133.49 | -350.89 | -106.73 | -38.39 | -42.77 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 19.48 | 21.23 | 40.33 | 506.01 | 414.59 |
Issuance (Repayment) of Debt | -5.81 | -5.41 | -5.03 | -37.10 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 13.67 | 15.82 | 35.30 | 468.91 | 414.59 |
Effect of Exchange Rate Changes | -0.03 | -0.04 | 0.23 | -0.46 | -0.05 |
Net Change In Cash & Equivalents | 131.93 | -368.72 | -92.57 | 212.15 | 406.41 |
Cash at Beginning of Period | 227.35 | 596.07 | 688.64 | 476.49 | 70.09 |
Cash at End of Period | 359.28 | 227.35 | 596.07 | 688.64 | 476.49 |
Diluted Net EPS | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 |
Fiscal Year End for 10x Genomics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -255.10 | -206.15 | -113.16 | -50.75 |
Depreciation/Amortization & Depletion | NA | 43.62 | 31.91 | 20.49 | 8.77 |
Net Change from Assets/Liabilities | NA | 18.02 | 0.28 | -15.89 | -5.96 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 178.26 | 133.00 | 92.91 | 43.82 |
Net Cash From Operating Activities | NA | -15.20 | -40.96 | -15.65 | -4.13 |
Property & Equipment | NA | -48.60 | -45.15 | -29.92 | -4.56 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 183.02 | 166.47 | 146.13 | 125.24 |
Other Investing Activities | NA | -0.92 | -0.92 | -0.72 | -0.72 |
Net Cash from Investing Activities | NA | 133.49 | 120.39 | 115.49 | 119.96 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 19.48 | 13.87 | 9.50 | 2.40 |
Issuance (Repayment) of Debt | NA | -5.81 | -5.81 | -5.81 | -5.81 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 13.67 | 8.06 | 3.68 | -3.41 |
Effect of Exchange Rate Changes | NA | -0.03 | -0.11 | -0.03 | 0.02 |
Net Change In Cash & Equivalents | NA | 131.93 | 87.39 | 103.50 | 112.44 |
Cash at Beginning of Period | NA | 227.35 | 227.35 | 227.35 | 227.35 |
Cash at End of Period | NA | 359.28 | 314.74 | 330.85 | 339.79 |
Diluted Net EPS | NA | -0.42 | -0.79 | -0.53 | -0.44 |